Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - rivastigmine hydrogen tartrate - capsules hard - 3 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - rivastigmine hydrogen tartrate - capsules hard - 4.5 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - rivastigmine hydrogen tartrate - capsules hard - 6 milligram

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - aprepitant, quantity: 80 mg - capsule, hard - excipient ingredients: hypromellose; sodium lauryl sulfate; gelatin; titanium dioxide; poloxamer; microcrystalline cellulose; sucrose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - aprepitant in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of:,? highly emetogenic cancer chemotherapy.,? moderately emetogenic cancer chemotherapy,aprepitant is indicated for the prevention of postoperative nausea and vomiting.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - aprepitant, quantity: 165 mg - capsule, hard - excipient ingredients: titanium dioxide; microcrystalline cellulose; gelatin; hypromellose; poloxamer; sucrose; sodium lauryl sulfate; indigo carmine aluminium lake; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - aprepitant in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of:,? highly emetogenic cancer chemotherapy.,? moderately emetogenic cancer chemotherapy,aprepitant is indicated for the prevention of postoperative nausea and vomiting.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - aprepitant, quantity: 125 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; sucrose; hypromellose; poloxamer; gelatin; sodium lauryl sulfate; titanium dioxide; iron oxide red; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - aprepitant in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of:,? highly emetogenic cancer chemotherapy.,? moderately emetogenic cancer chemotherapy,aprepitant is indicated for the prevention of postoperative nausea and vomiting.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - aprepitant, quantity: 40 mg - capsule, hard - excipient ingredients: iron oxide yellow; hypromellose; poloxamer; sucrose; gelatin; sodium lauryl sulfate; titanium dioxide; microcrystalline cellulose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - aprepitant in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of:,? highly emetogenic cancer chemotherapy.,? moderately emetogenic cancer chemotherapy,aprepitant is indicated for the prevention of postoperative nausea and vomiting.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dabigatran etexilate mesilate, quantity: 86.475 mg (equivalent: dabigatran etexilate, qty 75 mg) - capsule, hard - excipient ingredients: purified water; hypromellose phthalate; tartaric acid; butylated hydroxytoluene; hyprolose; microcrystalline cellulose; dichloromethane; purified talc; isopropyl alcohol; macrogol 600; citric acid monohydrate; ethanol; povidone; titanium dioxide; polyvinyl alcohol; macrogol 3350; sodium bicarbonate; methacrylic acid copolymer; macrogol 8000; hypromellose; sunset yellow fcf - dabigatran is indicated for prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dabigatran etexilate mesilate, quantity: 86.475 mg (equivalent: dabigatran etexilate, qty 75 mg) - capsule, hard - excipient ingredients: purified water; hypromellose phthalate; hyprolose; dichloromethane; tartaric acid; ethanol; butylated hydroxytoluene; povidone; purified talc; citric acid monohydrate; isopropyl alcohol; microcrystalline cellulose; macrogol 600; titanium dioxide; polyvinyl alcohol; macrogol 3350; sodium bicarbonate; methacrylic acid copolymer; hypromellose; sunset yellow fcf; macrogol 8000 - dabigatran is indicated for prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dabigatran etexilate mesilate, quantity: 86.475 mg (equivalent: dabigatran etexilate, qty 75 mg) - capsule, hard - excipient ingredients: citric acid monohydrate; butylated hydroxytoluene; dichloromethane; microcrystalline cellulose; ethanol; povidone; tartaric acid; macrogol 600; purified talc; isopropyl alcohol; hyprolose; hypromellose phthalate; purified water; titanium dioxide; hypromellose; sunset yellow fcf; macrogol 8000; polyvinyl alcohol; macrogol 3350; sodium bicarbonate; methacrylic acid copolymer - dabigatran is indicated for prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.